• Sonuç bulunamadı

血管收縮素

N/A
N/A
Protected

Academic year: 2021

Share "血管收縮素"

Copied!
2
0
0

Yükleniyor.... (view fulltext now)

Tam metin

(1)

血管收縮素 II 活化腎絲球體環間膜細胞磷脂醯肌醇 3 激酶 ; 之訊息傳遞 路徑及 HIF-1α 的累積

血管收縮素 II 會在人體血管組織釋放血管內皮生長因子 (VEGF) ,並調節 VEGF 引起血 管增生,而血管增生為糖尿病腎病變發展的主要病理過程。因此血管收縮素 II (angioten sin II , Ang II) 為潛在導致腎硬化的病因。由於在血管平滑肌細胞中 HIF-1a 會影響 VE GF 表現,本研究主要探討血管收縮素 II 在腎絲球體環間膜細胞是否會刺激 HIF-1α 的 增加,並了解其訊號傳遞路徑。在腎絲球環間膜細胞中,血管收縮素 II 可以活化磷脂 醯肌醇 3 激酶 (PI 3-kinase , PI3-K) 路徑並造成 PDK1 及 Akt 的磷酸化,同時也會造成 HIF-1α 堆積,由於 PI3-K 之抑制劑 LY294002 可抑制血管收縮素 II 所刺激的 HIF-1α 增加,血管收縮素 II 應是經由 PI3-K 路徑而造成 HIF-1α 堆積,且 HIF-1α 表現與血管 增生有關,因此血管收縮素 II 可能經 PI3-K 路徑而造成 HIF-1α 的累積,並進一步產生 血管增生情形,本研究將有助於了解腎絲球硬化時血管收縮素 II 所扮演的角色。

除此之外血管收縮素 II 也可以藉由訊號傳遞調控細胞凋亡以決定細胞之存亡。血管收 縮素 II 有兩條路徑可調控細胞生存;在 PC12W cells 中血管收縮素 II 可藉著合成 sphing omyelin ,及活化神經磷脂酵素 (sphingomyelinase) 而細胞內產生 ceramide 並造成細 胞凋亡。另外,血管收縮素 II 則可透過活化 cAMP 、 PI3-K 等訊號路徑使細胞生長。

故本論文第二部分探討 PI3-K 及神經磷脂酵素兩條路徑間之調控關係,進而了解血管收 縮素 II 調節腎絲球體環間膜細胞生長平衡之訊號傳遞方式。結果發現以血管收縮素 II 或 cAMP 處理腎絲球體環間膜細胞 30 分鐘可經由 PI3-K 路徑而活化下游之 PDK1 、 Ak t 之磷酸化;但若以神經醯胺 (ceramide) 或 cAMP 前處理腎絲球體環間膜細胞,則可將 血管收縮素 II 所活化之 Akt 去磷酸化;因此血管收縮素 II 可能藉由 PI3-K 及 cAMP 活 化 Akt 之路徑使細胞增生,另外又可透過神經醯胺 (ceramide) 活化 PKCζ 抑制細胞存 亡訊號 Akt 之活化,結論為 PI3-K 、 cAMP 與神經醯胺 (ceramide) 之訊號路徑間 cross- talk ,可藉此調節腎絲球體環間膜細胞生長平衡。

(2)

Angiotensin II activaties PI 3-kinase dependent pathway and HIF-1α accumulation in glomerular mesangial cells

The potential pathogenic role of angiotensin-II (Ang II) in glomeruloscerosis is not clear. Angiogenesis is one the major features of several pathological processes of a number of nephropathies. Ang II stimulates th e release of vascular endothelial growth factor (VEGF) from human vascular tissues. VEGF is a family of p otent cytokines, which act to induce angiogenesis. VEGF is up-regulated by Ang II during angiogenesis in hamster sponge granulomas. On the other hand, hypoxia-inducible factor-1 (HIF-1) controls the expression of a number of genes including vascular endothelial growth factor (VEGF) in vascular smooth muscle cells . We hypothesized that angiogenesis is induced by hypoxic conditions and regulated by the hypoxia-induci ble factor 1 (HIF-1). In the present study, we investigate whether Ang II stimulates the accumulation of HI F-1a and the role of PI3-K signaling pathway in this effect. We demonstrated that Ang II (100 nM) increas e HIF-1a protein expression in mesangial cells. Ang II (100 nM) activated PI3-K, PDK-1 and Akt in a dose dependent manner. Because Ang II-induced HIF-1a expression was blocked by the PI3-K inhibitor (LY294 002). The induction of HIF-a by Ang II is mediated through PI3-K dependent pathway.

Angiotensin II mediates both pro- and anti-apoptotic signaling cascades that determine survival and death decisions. In PC12W cells, Ang II induces sphingomyelin synthesis, which in turn leads to an increase in i ntracellular ceramide and apoptosis. Conversely, PI3-K is involved in regulating cell survival and prolifera tion pathways. Akt is a major downstream target of PI3-K involved in angiotensin II-induced proliferation.

In the present study, we investigate cross-talk between the PI3-K and sphingomyelinase pathways as a mec

hanism for regulation of mesangial cell survival/death decisions. Ang II (100 nM) exposure of rat mesangi

al cells activated PI3-K, PDK-1 and Akt in a dose dependent manner. The Ang II-stimulated effects can be

mimicked by incubating mesangials cells with dibutyryl cAMP. Treatment of the cells with C2-ceramides

blocked Ang II- or cAMP- induced PI3-K and Akt activation and results in a significant increase in cell dea

th. As a composite, these studies suggest that Ang II mediates proliferation pathway through cAMP and PI

3-K/Akt/PKB pathways, whereas ceramides and activation of PKCz inhibits the survival signal.

Referanslar

Benzer Belgeler

Efficacy analysis was the changes in blood pressure and number of patients meeting their goal blood pressure before and after therapeutic interchange.. Safety analysis was to

Efficacy analysis was the changes in blood pressure and number of patients meeting their goal blood pressure before and after therapeutic interchange.. Safety analysis was to

Efficacy analysis was the cha nges in blood pressure and number of patients meeting their goal blood pressure before and after therapeutic interchange.. Safe ty analysis was to

被 MEK 的抑制劑 PD98059 及 JNK 的抑制劑 SP600125 所抑制。另一方面,西方 墨點分析法顯示,VEGF 蛋白最大表現量在 8 小時,ERK1/2 的磷酸化則在 15 分 鐘最強。此外,VEGF

臺北醫學大學今日北醫: 邁向國際,追求卓越 打造卓越的語言學習環境 重仁) ---

可抑制血管收縮素 II 所刺激的 HIF-1α 增加,血管收縮素 II 應是經由 PI3-K 路 徑而造成 HIF-1α 堆積,且 HIF-1α 表現與血管增生有關,因此血管收縮素 II 可能經

本試驗採收 39 位健康成年人之尿液做為對照組,並且將糖尿病(n = 74)與高血壓(n = 81) 患者分別分為三組:未服用 valsartan,服用 valsartan 12 週,以及服用 valsartan

The purposes of this study were to understand and compare the differences in medical costs and ratios among different diagnoses, patient characteristics, hospital